Clinical trial NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
Official title: A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Hematologic Malignancies
Keywords: Acute Myeloid Leukemia,
AML
Lymphoma
Chronic Lymphocytic Lymphoma
CLL
Small Lymphocytic Lymphoma
SLL
relapsed
refractory
CDK9 inhibitor
GFH009
SLS009
venetoclax
azacitidine
ASXL1
Lead sponsor: Sellas Life Sciences Group
Sponsor class: INDUSTRY
First posted: 2020-10-19
Enrollment: 160
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Open Label, Multi-center
Primary purpose: TREATMENT

Brief summary: SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five cohorts of the expansion Group 3.

Detailed description: SLS009 is a potent and highly selective CDK9 inhibitor. This study is investigating the safety, tolerability, and antitumor activity of SLS009 in patients with hematologic malignancies in three groups (two dose escalation groups and one expansion group). The safety and efficacy of SLS009 as a single agent are assessed in Group 1 (patients with relapsed/refractory AML) and Group 2 (patients with relapsed/refractory lymphoma/CLL/SLL). The safety and efficacy of SLS009 in combination with venetoclax and azacitidine in patients with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five different cohorts in the expansion Group 3. The cohorts in Group 3 include three cohorts to assess different dose levels (Cohorts 1, 2, and 3), a cohort enrolling patients with r/r AML and ASXL1 mutations and a cohort enrolling patients with r/r AML with other myelodysplasia-related mutations other than ASXL1.

Eligibility criteria: Inclusion Criteria

1. Male or female ≥ 18 years. and pediatric patients ages 12-18 and ≥40 kg body mass
2. Patients with cytological or histologically confirmed relapsed or refractory hematologic malignancies (AML, CLL/SLL and lymphoma)

   * Lymphoma: At least one measurable or evaluable lesion as defined by the Lugano (2014) response criteria. Patients must have received at least 2 prior lines of systemic therapy.
   * AML (only for Group 3): Patients relapsed on or refractory to venetoclax containing regimens.

     * AML, Cohort 4 (ASXL1 mutations): AML patients relapsed on and/or refractory to therapies containing venetoclax combinations and with documented ASXL1 mutation.
     * AML, Cohort 5 (Other than ASXL1 Myelodysplasia related AML defining somatic mutations): AML patients relapsed on and/or refractory to therapies containing venetoclax combinations and with documented Defining somatic mutations, Cytogenetic abnormalities defining acute myeloid leukemia, myelodysplasia related, other than ASXL1 mutation per WHO 5th Edition classification (The 5th edition of the World Health Organization Classification of Hematolymphoid Tumors: Myeloid and Histiocytic/Dendritic Neoplasms). Mutations in Cohort 5 include: BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1 and ZRSR2. If any of those mutations is present concurrently with ASXL1 mutation, patients will be enrolled in Cohort 4 (ASXL1 mutation) and only patients harboring the above listed mutations without concurrent ASXL1 mutation will be enrolled in Cohort 5 (Other than ASXL1 Myelodysplasia related AML defining somatic mutations).
3. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) except for patients with Gilbert's syndrome, who are included if total bilirubin is \< 3 × ULN or if direct bilirubin is \< 1.5 × ULN.

   • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 × ULN. For those with hepatic metastases, AST and ALT ≤ 5 × ULN.
4. Measured or calculated (determined by the Cockcroft-Gault equation) serum creatinine clearance (CrCl) ≥ 60 mL/min (glomerular filtration rate can be an alternative to CrCl).) for adult patients or serum creatinine ≤ 1.5 x ULN; or if serum creatinine \> 1.5 x ULN, then serum creatinine clearance (CrCl) ≥ 50 mL/min (estimated by Cockcroft-Gault formula or other appropriate formula) for pediatric patients. Whether the value is calculated by equation or measured directly can be based on institutional standard practice.
5. Amylase ≤1.5 × ULN
6. Electrolytes and uric acid level need to be stable judged by investigators for at least 3 days before the first dose of SLS009 (formerly GFH009) (Medical intervention is permitted).
7. For women of childbearing potential, must consent to use highly effective methods (ie, total abstinence, placement of an intrauterine device) of contraception during SLS009 (formerly GFH009) treatment and for an additional 90 days after the last administration of study drug, if enrolled in Groups 1 or 2, and 6 months if enrolled in Group 3. Men with a partner of childbearing potential, must consent to use two highly effective methods of contraception during SLS009 (formerly GFH009) treatment and for an additional 90 days after the last administration of study drug.

Exclusion Criteria

1. Patients with bulky disease (≥ 10 cm) who require cytoreductive therapy.
2. Symptomatic central nervous system metastases or primary lymphoma such as primary CNS lymphoma, leptomeningeal disease, or spinal cord compression. Patients with asymptomatic CNS metastases who are radiologically and neurologically stable ≥ 4 weeks following CNS-directed therapy and are on a stable or decreasing dose of corticosteroids are eligible for study entry.
3. Severe cardiovascular disease within 6 months of study entry, including any of the following:

   * Clinically significant heart disease such as congestive heart failure requiring treatment (NYHA class III or IV), LVEF \< 50% as determined by MUGA scan or echocardiogram (ECHO), (if only with historical occasional low LVEF but without any symptoms or relevant medical history, and the LVEF at screening is \> 50%, the subject is eligible), or clinically significant arrythmia.
   * History/evidence of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft (CABG), coronary angioplasty, or stenting).
   * Average QTcF ≥ 450 msec (males) or ≥ 470 msec (females) on screening ECG.
   * Moderate or above regurgitation on echocardiogram
   * Patients with prior treatment with cardiotoxic agents who have experienced drug induced cardiotoxicities during or after treatment, where cardiotoxic agents include but are not limited to: anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone); trastuzumab and trastuzumab based ADCs; tyrosine kinase inhibitors (sunitinib, imatinib); alkylating agents (cyclophosphamide).
   * Patients with a baseline cardiac biomarker abnormality (CKMB/cTnI) will be excluded.
4. Patients with hypereosinophilic syndrome defined as eosinophil counts in peripheral blood of ≥1,500/µ.
5. Concurrent malignancy within 5 years (for AML patients, 2 years) prior to entry other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer not requiring treatment, ductal carcinoma in situ of the breast, and superficial non-muscle invasive urothelial carcinoma (excluding T1 lesions and CIS).
6. Active hepatitis B or hepatitis C virus infection.
7. History of HIV infection or HIV positive at screening.
8. Concomitant medications that are strong CYP3A4 inhibitors and strong inducers within 7 days prior to the first dose. Avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pomelos, star citrus fruits or St. John's wort within 7 days of first dose.
9. Medications that are known to prolong the QT interval that could not be stopped prior to study entry judged by investigator, except azole antifungal medications in AML patients.
10. Subjects with high risk of gastrointestinal hemorrhage, including but not limiting to: active ulcer with fecal occult blood test ≥++; history of haematemesis or melena within 2 months prior first dose.

Primary outcomes:
measure: Safety and Tolerability: Dose Limiting Toxicities (DLTs)
timeFrame: 21 to 28 days
measure: Safety and Tolerability: adverse events (AEs)
timeFrame: approximately 2 years
Secondary outcomes:
measure: PK parameter AUC0-t
timeFrame: approximately 3 months
measure: PK parameter AUC0-∞
timeFrame: approximately 3 months
measure: Efficacy: ORR
timeFrame: 2 years
measure: Efficacy: DOR
timeFrame: 2 years
measure: Efficacy: PFS
timeFrame: 2 years
measure: Efficacy:OS
timeFrame: 2 years
measure: PK parameter Cmax
timeFrame: approximately 3 months
measure: PK parameter Tmax
timeFrame: approximately 3 months
measure: PK parameter t½
timeFrame: approximately 3 months
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: O'Neal Comprehensive Cancer Center, University of Alabama
state: Alabama
city: New Orleans
country: United States
facility: Ochsner Clinic Foundation
state: Louisiana
city: Lake Success
country: United States
facility: Clinical Research Alliance, Inc.
state: New York
city: New York
country: United States
facility: New York - Presbyterian Hospital
state: New York
city: Chapel Hill
country: United States
facility: UNC School of Medicine, Division of Hematology
state: North Carolina
city: Greenville
country: United States
facility: Bon Secours St. Francis Cancer Center
state: South Carolina
city: Dallas
country: United States
facility: Baylor Scott & White Health
state: Texas
city: Houston
country: United States
facility: MD Anderson
state: Texas
city: Bengbu
country: China
facility: The First Affiliated Hospital of Bengbu Medical College
state: Anhui
city: Hefei
country: China
facility: Anhui Provincial Hospital
state: Anhui
city: Chongqing
country: China
facility: Affiliated Cancer Hospital of Chongqing University
state: Chongqing
city: Guangzhou
country: China
facility: Cancer prevention and treatment center of Sun Yat sen University
state: Guangdong
city: Guangzhou
country: China
facility: Guangdong Provincial People's Hospital
state: Guangdong
city: Baoding
country: China
facility: Affiliated Hospital of Hebei University
state: Hebei
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University
state: Jiangsu
city: Nanchang
country: China
facility: The First Affiliated Hospital Of Nanchang University
state: Jiangxi
city: Shenyang
country: China
facility: Shengjing Hospital Affiliated to China Medical University
state: Liaoning
city: Linyi
country: China
facility: Linyi Cancer Hospital
state: Shandong
city: Tianjin
country: China
facility: Blood disease hospital, Chinese Academy of Medical Science
state: Tianjin
city: Hangzhou
country: China
facility: The Second Affiliated hospital of Zhejiang University School of Medicine
state: Zhejiang
Study officials:
affiliation: SELLAS Life Sciences Group, Inc.
name: Dragan Cicic, MD
role: STUDY_CHAIR
References: